An Open-Label, Multicenter Trial to Validate the Quality of Life Questionnaire-Bronchiectasis and to Evaluate Perception of Symptom Improvement Following One Course of Aztreonam for Inhalation Solution (AZLI) in Subjects With Bronchiectasis and Gram-Negative Bacteria in the Airways.

Trial Profile

An Open-Label, Multicenter Trial to Validate the Quality of Life Questionnaire-Bronchiectasis and to Evaluate Perception of Symptom Improvement Following One Course of Aztreonam for Inhalation Solution (AZLI) in Subjects With Bronchiectasis and Gram-Negative Bacteria in the Airways.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2014

At a glance

  • Drugs Aztreonam (Primary)
  • Indications Bronchiectasis; Gram-negative infections
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 25 Feb 2010 Actual patient number (92) added as reported by ClinicalTrials.gov.
    • 25 Feb 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 25 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top